Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) — Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders […]
On Monday, Helus Pharma (NASDAQ:HELP) shareholders gathered for their annual and special meeting, with 107 representatives voting in favor of key resolutions. The company's name change from Cybin Inc. to Helus Pharma Inc. received overwhelming support at 99.32% approval, set to take effect on October 1, 2026. Out of eight directors elected for the following year, all received high approval ratings, ranging from 71.32% to 99.72%.
The meeting also saw the appointment of Zeifmans LLP as the company's auditor until the next annual gathering, with 99.21% of votes cast in its favor. Helus Pharma, a clinical-stage pharmaceutical firm, focuses on developing synthetic molecules to activate serotonin pathways, with HLP003 currently in Phase 3 trials for major depressive disorder and HLP004 in Phase 2 development for generalized anxiety disorder.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
